患有的人具有高辐射敏感性,可通过叶酸减轻
Melissa Kleber1, Lukas C F Kuhlmann1, Anabel Knabe1
1Department of Radiation Oncology, Universitätsklinikum Erlangen, Friedrich-Alexander University of Erlangen-Nürnberg (FAU), Universitätsstraße 27, 91054, Erlangen, Germany.
Journal of neurology
|January 8, 2026
概括
与健康人群和癌症患者相比,患者 (PWE) 的放射敏感性增加. 男性PWE更敏感,可能是由于更低的叶酸摄入量,这可以防止辐射.
科学领域:
- 在瘤学瘤学.
- 辐射生物学 辐射生物学
- 神经学 神经学
背景情况:
- 癌症患者的并发症和药物可以改变正常组织的辐射敏感性.
- 由于潜在的混因素,研究患者 (PWE) 的辐射敏感性至关重要.
研究的目的:
- 为了确定患有 (PWE) 的人是否表现出改变的辐射敏感性.
- 为了比较PWE对健康个体和癌症患者的辐射敏感性.
主要方法:
- 来自105名PWE,健康个体和癌症患者的血液样本被辐射出活体.
- 染色体异常被分析使用3色光在现场杂交.
- 辐射敏感性是通过每次元相平均断裂 (B/M) 来量化.
主要成果:
- PWE (B/M:0.478) 显示放射敏感性明显高于健康人群 (B/M:0.420) 和癌症患者 (B/M:0.442).
- 一些抗发作药物,包括perampanel和lacosamide,与辐射敏感性增加有关.
- 男性PWE (B/M:0.502) 比女性PWE更容易受到辐射,这可能与叶酸摄入有关.
结论:
- 与健康和癌症患者队伍相比,患有 (PWE) 的人具有较高的辐射敏感性.
- 男性PWE表现出增加的辐射敏感性,可能受到叶酸水平的影响.
- 研究结果表明,需要考虑PWE的辐射敏感性,特别是在接受放射治疗时.
相关概念视频
Antiepileptic Drugs: Glutamate Antagonists
884
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
884
Epilepsy and Seizures: Overview
1.1K
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
1.1K
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
806
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
806
Antiepileptic Drugs: Sodium Channel Blockers
1.6K
Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
1.6K
Antiepileptic Drugs: Potassium Channel Activators
624
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
624
Antiepileptic Drugs: GABAergic Pathway Potentiators
1.2K
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
1.2K


